| Efficacy analysis of combined albumin-bound paclitaxel with tegaful regimen in gastric cancer patients with peritoneal metastasis as first-line treatment |
| Received:July 04, 2020 Revised:October 28, 2020 Click here to download the full text |
| Citation of this paper:TANG Cheng,WANG Yan,YU Shan,SHEN Zhen-bin,XIONG Sang,HOU An-ji,LIU Tian-shu,CUI Yue-hong.Efficacy analysis of combined albumin-bound paclitaxel with tegaful regimen in gastric cancer patients with peritoneal metastasis as first-line treatment[J].Chinese Journal of Clinical Medicine,2020,27(6):983-987 |
| Hits: 1663 |
| Download times: 535 |
| Author Name | Affiliation | E-mail | | TANG Cheng | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | WANG Yan | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | YU Shan | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | SHEN Zhen-bin | Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | XIONG Sang | Department of Medical Oncology, Xuhui Central Hospital, Shanghai 200031, China | | | HOU An-ji | Department of Medical Oncology, Xuhui Central Hospital, Shanghai 200031, China | | | LIU Tian-shu | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CUI Yue-hong | Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | cui.yuehong@zs-hospital.sh.cn |
|
| Abstract:Objective:To explore the efficacy of albumin-bound paclitaxel (Abraxane) combined with tegafur (S-1) in the treatment of peritoneal metastasis of gastric cancer.Methods:Clinical data of 18 gastric cancer patients with peritoneal metastasis admitted to Zhongshan Hospital, Fudan University and Xuhui District Central Hospital of Shanghai from September 2018 to December 2019 and treated by AS (Abraxane plus S-1) regimen were retrospectively analyzed, and 10 patients with middle-large ascites were treated by abdominocentesis and intraperitoneal injection only once. All patients were treated with AS (Abraxane plus S-1) regimen during their first-line treatment. Abraxane (125 mg/m2, d1 and d8) and S-1 (80 mg/m2, bid, d1-14) were administered every 3 weeks. If no disease progression occurred after 6 cycles of chemotherapy, Abraxane and S-1 would be administered alternately as a subsequent maintenance treatment. CT evaluation and regular follow-up were conducted every 3 months.Results:Totally, 10 males and 8 females were enrolled with a median age of 58.5 years. The median progression-free survival (PFS) time and overall survival (OS) time was (10.00±2.51) months and (14.00±0.85) months, respectively. Meanwhile, the overall response rate (ORR) and disease control rate (DCR) of these patients was 44.44% and 77.78%, respectively. There were 10 patients with peritoneal metastasis and malignant ascites. The median PFS of patients with or without ascites was (7.00±1.46) months and (11.00±1.28) months, respectively (P=0.43). The main adverse events were hand-foot syndrome, alopecia, diarrhea, and neutropenia.Conclusion:AS regimen exhibited promising efficacy and well tolerance in first-line treatment of gastric cancer patients with peritoneal metastasis. Precise treatment against specific target might prolong survival time. |
| keywords:gastric cancer peritoneal metastasis albumin-bound paclitaxel tegaful |
| HTML View Full Text View/Add Comment Download reader |
|
|
|